Table 3 Crude incidence rates and incidence rate ratios of 11 study outcomes among asthma patients, stratified by non-use, ever use, and current use of oral prednisolone

 Cases, n

6174

5867

591

10,115

2882

3534

3639

1057

6034

3602

2868

 Person-years

509,914

493,646

631,164

567,254

614,128

609,903

618,128

633,404

616,192

402,782

607,320

 IR/ 1000 person-years (95% CI)

12.1 (11.8–12.4)

11.9 (11.6–12.2)

0.9 (0.9–1.0)

17.8 (17.5–18.2)

4.7 (4.5–4.9)

5.8 (5.6–6.0)

5.9 (5.7–6.1)

1.7 (1.6–1.8)

9.8 (9.5–10.0)

8.9 (8.7–9.2)

4.7 (4.5–4.9)

 Cases, n

2753

2295

245

6077

1293

1661

1717

416

2791

1363

1160

 Person-years

172,484

159,919

219,711

177,156

210,560

210,152

212,161

220,804

208,916

122,796

209,638

 IR/1000 person-years (95% CI)

16.0 (15.4–16.6)

14.4 (13.8–14.9)

1.1 (1.0–1.3)

34.3 (33.4–35.2)

6.1 (5.8–6.5)

7.9 (7.5–8.3)

8.1 (7.7–8.5)

1.9 (1.7–2.1)

13.4 (12.9–13.9)

11.1 (10.5–11.7)

5.5 (5.2–5.9)

 IRR (95% CI)

1.3 (1.3–1.4)

1.2 (1.2–1.3)

1.2 (1.0–1.4)

1.9 (1.9–2.0)

1.3 (1.2–1.4)

1.4 (1.3–1.4)

1.4 (1.3–1.5)

1.1 (1.0–1.3)

1.4 (1.3–1.4)

1.2 (1.2–1.3)

1.2 (1.1–1.3)

 Cases, n

533

451

51

2268

257

398

272

62

541

269

236

 Person-years

29,141

27,032

36,864

29,074

35,586

35,468

35,723

37,125

35,364

19,803

35,269

 IR/1000 person-years (95% CI)

18.3 (16.7–19.8)

16.7 (15.1–18.2)

1.4 (1.0–1.8)

78.0 (74.8–81.2)

7.2 (6.3–8.1)

11.2 (10.1–12.3)

7.6 (6.7–8.5)

1.7 (1.3–2.1)

15.3 (14.0–16.6)

13.6 (12.0–15.2)

6.7 (5.8–7.5)

 IRR (95% CI)

1.5 (1.4–1.6)

1.4 (1.3–1.5)

1.5 (1.1–2.0)

4.4 (4.2–4.6)

1.5 (1.4–1.7)

1.9 (1.7–2.2)

1.3 (1.1–1.5)

1.0 (0.8–1.3)

1.6 (1.4–1.7)

1.5 (1.3–1.7)

1.4 (1.2–1.6)